| Posters on Seroquel |
An Open-Label Trial of Quetiapine for Antipsychotic-Induced Sexual Dysfunction
Author: M Byerly, 1 January 2002
Objectives: Sexual dysfunction is a common side effect of antipsychotic treatment. The primary objective of the present study was to evaluate the effect of switching patients with... |
Effects on Weight Change of Switching From Olanzapine to Quetiapine
Author: PS Masand, 1 January 2002
Objective: To assess effects of switching from olanzapine to quetiapine on body weight in chronically psychiatrically ill patients. Methods: Sixteen patients who were psychiatrically stable on... |
Patients with Schizophrenia Switching to Quetiapine Gain Clinical Benefit
Author: H Rittmannsberger, 1 January 2002
Objective: The atypical antipsychotic quetiapine is effective and well tolerated in patients with schizophrenia. This trial examines the clinical benefit of quetiapine in patients with schizophrenia... |
Switching Patients to Quetiapine Improves Depressive Symptoms in Schizophrenia
Author: Irmansyah, 1 January 2002
Introduction: Quetiapine is known to reduce depressive symptoms in patients with schizophrenia. This analysis examines the benefits that switching to quetiapine from suboptimal therapy with... |
Successful Methodology for Switching Patients to Quetiapine: A Multicenter Open-Label Trial in Schizophrenia
Author: E Windhager, 1 January 2002
Objective: Quetiapine is well tolerated and effective in patients with schizophrenia. This study aimed to determine the clinical benefit of switching patients to quetiapine. Methods: This was a... |
Improved efficacy gained from switching to quetiapine in patients with schizophrenia
Author: A De Nayer, 1 January 2002
Purpose: Patients with an inadequate response or intolerance to their current antipsychotic therapy may benefit from switching to another antipsychotic. Since the atypical antipsychotic, quetiapine... |
Switching to quetiapine improves drug tolerability in patients with schizophrenia with intolerance or inadequate response to previous therapy
Author: I Larmo, 1 January 2002
Purpose: In this open, non-comparative trial the tolerability of quetiapine (‘Seroquel’) was assessed in patients switched from previous antipsychotic treatment because of intolerance or inadequate... |
Seroquel clinical use in real-life environment – the SECURE study
Author: B. Gillain, 1 January 2002
The SECURE Study is a Phase IV, twelve-week open-label, non-comparative, and multicentre study designed to assess the efficacy and tolerability in schizophrenic patients who are switched to... |
Tolerability and effectiveness of three methods of switching to quetiapine
Author: J Jiménez, 1 January 2002
OBJECTIVE: Defined methods for switching antipsychotic therapies, particularly from conventional to newer atypical agents, are important components of patient management. A clear understanding of the... |
Sexual functioning during long-term quetiapine treatment for schizophrenic patients in a naturalistic setting
Author: J Bobes, 1 January 2002
OBJECTIVE: Sexual dysfunction is a common and troublesome side effect of psychotropics including antipsychotics and it is significantly associated with low levels of patient satisfaction with... |
A Health Economic Evaluation of Quetiapine Compared with Risperidone: a Supplemental Analysis of the QUEST Trial
Author: WR Simons, 1 January 2001
Comparative cost-effectiveness was assessed in a supplemental analysis of a 4-month multicentre, open-label, randomised trial (QUEST) that compared the efficacy and safety of quetiapine with... |
Comparison of the Effects of Quetiapine and Haloperidol in a Cohort of Patients With Treatment-Resistant Schizophrenia
Author: P Buckley, 1 January 2001
Study: To compare the efficacy and tolerability of quetiapine and haloperidol in patients resistant to fluphenazine Methods: Patients with treatment-resistant schizophrenia received fluphenazine... |
NR610: Quetiapine Effective in Reducing Anxiety: Clinical Evidence
Author: AJ Cutler, 1 January 2001
Objective: Quetiapine has proven short-term and long-term efficacy in the treatment of acute and chronic stable schizophrenia. Its favorable tolerability profile includes no greater incidence... |
NR258: Quetiapine Improves Cognitive Function in Schizophrenia
Author: HY Meltzer, 1 January 2001
Objective: To examine the effect of clozapine and quetiapine on working memory after 6 weeks of treatment in schizophrenia. Methods: To assess the effect of 6 weeks’ quetiapine treatment on... |
NR538: Safety Update on Lenticular Opacities: Benign Experience With Quetiapine
Author: AM Laties, 1 January 2001
Objective: To assess the incidence of lens opacities with quetiapine. Method: The package insert for quetiapine in Canada and the US recommends patients undergo periodic eye exams to check for... |
Maintenance of Long-term Efficacy With Quetiapine
Author: IW RAk, 1 January 2000
Background: Long-term clinical trials are required to establish whether initial responses to atypical antipsychotic treatment are maintained. Objectives: To demonstrate that clinical improvements... |
Atypical Antipsychotics Have Equivalent Efficacy in Treating Negative Symptoms of Psychosis
Author: C Schultz, 1 January 2000
Atypical antipsychotics (clozapine, risperidone, olanzapine, and quetiapine) have been found to be more effective than conventional antipsychotics in treating the negative symptoms of psychosis.... |
Incidence of Persistent Tardive Dyskinesia may be Lower with Quetiapine Treatment than Previously Reported with Typical Antipsychotics in Patients with Psychoses
Author: WM Glazer, 1 January 2000
Tardive dyskinesia (TD) is often a serious side effect of antipsychotic drug treatment, because these involuntary, hyperkinetic, abnormal movements are potentially irreversible. Although the... |
Efficacy of ‘Seroquel’ (Quetiapine) Compared with Haloperidol and Placebo in the Short-term Treatment of Acute Schizophrenia
Author: S Charles Schulz, 1 January 2000
Background: The efficacy of quetiapine (‘Seroquel’) in relieving the positive and negative symptoms of schizophrenia has been demonstrated in a number of controlled and open-label extension... |
Changes In Cognitive Functioning With Quetiapine Fumarate Versus Haloperidol
Author: DI Velligan, 1 January 1999
Objective: Recent evidence suggests that schizophrenia patients taking novel antipsychotic medications may perform better on some tests of neurocognitive ability than those treated with older... |
Efficacy and Tolerability of ‘Seroquel’ Compared with Haloperidol in Schizophrenic Patients Partially Responsive to Conventional Antipsychotic Treatment
Author: RA Emsley, 1 January 1999
Many schizophrenic patients respond only partially to conventional antipsychotics. This international, multicentre, double-blind, randomised study compared the efficacy and safety of quetiapine... |
‘Seroquel’ (Quetiapine): Efficacy in Improving Mood, Aggression and Hostility
Author: J.S.E. Hellewell, 1 January 1998
'Seroquel' (quetiapine), an atypical antipsychotic, has been demonstrated in a clinical trial programme to be effective in the treatment of schizophrenia with no greater EPS than placebo across the... |
Attitudes towards the treatment of schizophrenia and perceptions of antipsychotic side effects: a multinational survey of psychiatrists, nurses, patients and caregivers
Author: Jonathan S.E. Hellewell, 1 January 1999
Purpose: A multinational survey was undertaken to gather and compare the views of medical professionals, patients with schizophrenia, caregivers and support groups towards the incidence of... |
'Seroquel': Efficacy in Aggression, Hostility and Low Mood of Schizophrenia
Author: J.S.E. Hellewell, 1 January 1999
Quetiapine (‘Seroquel’) is an atypical antipsychotic which is clinically effective in the treatment of schizophrenia while associated with an incidence of EPS no greater than placebo across the full... |
A multinational survey of patient satisfaction with long-term 'Seroquel' (quetiapine fumarate) treatment
Author: Jonathan S. E. Hellewell, 1 January 1998
Assessment of treatment satisfaction has become particularly important for patients with chronic diseases, as patients’ subjective experience of medication has been shown to influence compliance and,... |
